News Releases

Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million. Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors. Maintaining substantial cash, cash equivalents, and

Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic’s platform while expanding footprint to San Diego, CA BOULDER, Colo. and SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI

BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio

BOULDER, Colo. and BINYAMINA, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy.

BOULDER, Colo., June 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following conferences. Jefferies Healthcare Conference June 8-9, 2022, in New York 7th Annual MarketsandMarkets

Company to host conference call today at 4:30 p.m. ET BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another

BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding

SomaScan® platform study utilizing 32,000 samples showed a 27-protein test is a uniquely superior surrogate for cardiovascular outcomes BOULDER, Colo., April 12, 2022 (GLOBE NEWSWIRE) -- In one of the largest proteomic studies ever conducted and published April 6 in the journal Science

Fourth quarter 2021 revenue of $23.0 million contributed to record full year revenue of $81.6 million, 46% growth over the prior year Established over 75 new customer accounts, expanding and diversifying revenue base Substantial cash and investments of $657.7 million at year-end Maintaining 2022

BOULDER, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the European Prospective Investigation into Cancer and Nutrition (EPIC) study beginning in the first quarter